Skip to content

Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.

Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04363099
Acronym
COVID AMBU 60
Enrollment
1000
Registered
2020-04-27
Start date
2020-03-01
Completion date
2020-12-31
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19

Keywords

ambulatory, outpatients, COVID 19, Oise, France

Brief summary

Since December 2019, a new agent, the coronavirus SARS-Cov-2, has spread from China to the rest of the world causing an international epidemic of respiratory diseases called COVID-19. Oise was one of the first clusters in France, with more than 4,000 confirmed cases. A significant proportion (80%) of patients with COVID-19 are ambulatory. However, few data are available for this particular population in France. Thus, few clear recommendations are available. We propose to conduct a large cohort of observation of suspected or confirmed COVID-19 patients on an ambulatory basis in the Oise region. This observatory will make it possible to describe the epidemiological characteristics and initial management of COVID-19 patients and to identify early severity factors.

Interventions

OTHERobservational

observational management of outpatients COVID 19

Sponsors

Maison de Sante Pluridisciplinaire de Creil
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 99 Years

Inclusion criteria

* patients with covid 19 symptoms * patients who had a contact with a person PCR Covid 19+

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frame
clinical description of covid 19 ambulatory cases.3 months

Secondary

MeasureTime frame
Biological and radiological description of ambulatory cases3 months
Prevalence of positive cases (PCR and/or serological positive)3 months

Countries

France

Contacts

Primary ContactSvetlane DIMI, M.D
svetlane.dimi@sfr.fr+33650002085

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026